MCID: PNC033
MIFTS: 63

Pancreas Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreas Adenocarcinoma

MalaCards integrated aliases for Pancreas Adenocarcinoma:

Name: Pancreas Adenocarcinoma 37 12
Pancreatic Adenocarcinoma 12 28 14
Adenocarcinoma of the Pancreas 12
Adenocarcinoma of Pancreas 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 46 C8294
SNOMED-CT 64 700423003
UMLS 69 C0281361

Summaries for Pancreas Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreas Adenocarcinoma, also known as pancreatic adenocarcinoma, is related to pancreatic cancer and pancreatic ductal adenocarcinoma, and has symptoms including pruritus, icterus and abdominal pain. An important gene associated with Pancreas Adenocarcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Abraxane and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreas Adenocarcinoma

Diseases related to Pancreas Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 31.6 AKT1 BRCA2 CDH1 CDKN2A HRAS KRAS
2 pancreatic ductal adenocarcinoma 31.5 AKT1 CDH1 CDKN2A HRAS KRAS MSLN
3 adenocarcinoma 30.6 AKT1 CDH1 CDKN2A HRAS KRAS MUC1
4 adenosquamous carcinoma 30.2 KRAS MUC1 MUC4 TP53
5 cholangiocarcinoma 30.1 CDH1 KRAS MUC1 MUC4 SMAD4
6 pancreatic acinar cell adenocarcinoma 11.0
7 pancreatitis 11.0
8 sigmoid neoplasm 10.7 HRAS KRAS
9 mutyh-associated polyposis 10.7 KRAS SMAD4 TP53
10 adenosquamous pancreas carcinoma 10.7 HRAS KRAS SMAD4
11 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
12 spitz nevus 10.7 CDKN2A HRAS TP53
13 lichen disease 10.7 FOXP3 IFNG TP53
14 pulmonic stenosis 10.7 HRAS KRAS MAP2K2
15 thyroid lymphoma 10.6 CDKN2A IL7 TP53
16 ovary adenocarcinoma 10.6 HRAS KRAS TP53
17 apocrine adenoma 10.6 HRAS KRAS MUC1
18 mixed cell type cancer 10.6 HRAS KRAS TP53
19 meningeal melanomatosis 10.6 CDKN2A HRAS TP53
20 aggressive digital papillary adenocarcinoma 10.6 HRAS KRAS MUC1
21 liver angiosarcoma 10.6 HRAS KRAS TP53
22 costello syndrome 10.6 HRAS KRAS MAP2K2
23 ampulla of vater neoplasm 10.6 HRAS KRAS MUC1
24 anal squamous cell carcinoma 10.6 AKT1 CDKN2A TP53
25 breast giant fibroadenoma 10.6 BRCA2 CDKN2A IFNG
26 acinar cell carcinoma 10.6 BRCA2 SMAD4 TP53
27 duodenum cancer 10.6 HRAS KRAS MUC1
28 cardiofaciocutaneous syndrome 1 10.6 HRAS KRAS MAP2K2
29 glycogen-rich clear cell breast carcinoma 10.6 BRCA2 CDKN2A TP53
30 barrett's adenocarcinoma 10.6 CDKN2A KRAS TP53
31 penile cancer 10.6 CDKN2A HRAS TP53
32 pancreatic mucinous cystadenoma 10.6 HRAS MUC1 PTF1A
33 lung benign neoplasm 10.6 HRAS KRAS TP53
34 acute necrotizing encephalitis 10.6 FOXP3 IFNG
35 pseudomyxoma peritonei 10.6 KRAS MUC1 TP53
36 primary peritoneal carcinoma 10.6 BRCA2 ERCC1 IFNG TP53
37 intestinal disease 10.6 FOXP3 IFNG TP53
38 pleural cancer 10.6 AKT1 CDKN2A MSLN
39 colorectal adenoma 10.6 HRAS KRAS TP53
40 nasal cavity adenocarcinoma 10.6 CDKN2A HRAS KRAS TP53
41 signet ring cell adenocarcinoma 10.6 CDH1 MUC1 TP53
42 in situ carcinoma 10.6 CDH1 CDKN2A TP53
43 lymphopenia 10.6 FOXP3 IFNG IL7
44 sensory system cancer 10.6 AKT1 CDKN2A TP53
45 leukemia, acute lymphoblastic 3 10.6 CDKN2A IL7 TP53
46 pancreatic ductal carcinoma 10.6 CDKN2A MUC1 SMAD4 TP53
47 cell type benign neoplasm 10.6 CDKN2A HRAS KRAS TP53
48 intestinal benign neoplasm 10.5 CDH1 HRAS KRAS TP53
49 biliary papillomatosis 10.5 HRAS KRAS MUC1 TP53
50 endometrial adenocarcinoma 10.5 CDKN2A KRAS TP53

Graphical network of the top 20 diseases related to Pancreas Adenocarcinoma:



Diseases related to Pancreas Adenocarcinoma

Symptoms & Phenotypes for Pancreas Adenocarcinoma

UMLS symptoms related to Pancreas Adenocarcinoma:


pruritus, icterus, abdominal pain

GenomeRNAi Phenotypes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.6 HRAS KRAS
2 Decreased viability GR00106-A-0 9.6 KRAS
3 Decreased viability GR00221-A-1 9.6 AKT1 CDH1 CDKN2A HRAS KRAS
4 Decreased viability GR00221-A-2 9.6 AKT1 HRAS KRAS
5 Decreased viability GR00221-A-3 9.6 AKT1 CDKN2A HRAS
6 Decreased viability GR00221-A-4 9.6 AKT1 CDKN2A
7 Decreased viability GR00301-A 9.6 CDH1 KRAS
8 Decreased viability GR00381-A-1 9.6 KRAS
9 Decreased cell migration GR00055-A-1 9.35 MUC1 AKT1 HRAS KRAS MAP2K2

MGI Mouse Phenotypes related to Pancreas Adenocarcinoma:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 TP53 FOXP3 ERCC1 HRAS BRCA2 CDKN2A
2 endocrine/exocrine gland MP:0005379 10.39 FOXP3 ERCC1 HRAS KRAS IFNG AKT1
3 growth/size/body region MP:0005378 10.38 TP53 FOXP3 ERCC1 HRAS BRCA2 CDKN2A
4 cellular MP:0005384 10.36 TP53 CDKN2A FOXP3 ERCC1 BRCA2 KRAS
5 homeostasis/metabolism MP:0005376 10.36 TP53 CDKN2A FOXP3 ERCC1 HRAS MAP2K2
6 cardiovascular system MP:0005385 10.33 TP53 HRAS CDKN2A FOXP3 MAP2K2 KRAS
7 digestive/alimentary MP:0005381 10.31 FOXP3 HRAS KRAS IFNG CDH1 MAP2K2
8 hematopoietic system MP:0005397 10.3 TP53 CDKN2A FOXP3 ERCC1 BRCA2 KRAS
9 immune system MP:0005387 10.27 TP53 CDKN2A FOXP3 ERCC1 BRCA2 KRAS
10 embryo MP:0005380 10.26 TP53 CDKN2A ERCC1 BRCA2 KRAS AKT1
11 integument MP:0010771 10.26 FOXP3 ERCC1 HRAS KRAS IFNG AKT1
12 mortality/aging MP:0010768 10.25 TP53 HRAS CDKN2A FOXP3 ERCC1 MAP2K2
13 craniofacial MP:0005382 10.18 TP53 HRAS FOXP3 MAP2K2 KRAS IFNG
14 neoplasm MP:0002006 10.15 IFNG ERCC1 HRAS AKT1 CDH1 MAP2K2
15 liver/biliary system MP:0005370 10.09 TP53 FOXP3 ERCC1 CDKN2A KRAS AKT1
16 normal MP:0002873 10.03 FOXP3 HRAS KRAS IFNG AKT1 CDH1
17 no phenotypic analysis MP:0003012 10.02 FOXP3 HRAS CDKN2A KRAS IFNG CDH1
18 limbs/digits/tail MP:0005371 10 TP53 FOXP3 BRCA2 KRAS SLC29A1 SMAD4
19 reproductive system MP:0005389 9.85 TP53 CDKN2A FOXP3 ERCC1 BRCA2 KRAS
20 respiratory system MP:0005388 9.56 TP53 HRAS CDKN2A FOXP3 KRAS AKT1
21 skeleton MP:0005390 9.44 ERCC1 HRAS KRAS IFNG AKT1 MAP2K2

Drugs & Therapeutics for Pancreas Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 45 PACLITAXEL Celgene October 2012
2
Gemzar 17 45 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Pancreas Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
4
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
5
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
6
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
7
Desflurane Approved Phase 4 57041-67-5 42113
8
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 1
20 Central Nervous System Depressants Phase 4,Phase 2
21 Anesthetics Phase 4,Phase 2,Phase 1
22 Anesthetics, General Phase 4
23 Anesthetics, Inhalation Phase 4
24
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
25
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
26
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
28
Irinotecan Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 97682-44-5, 100286-90-6 60838
29
Levoleucovorin Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 68538-85-2
30
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
31
Cisplatin Approved Phase 2, Phase 3, Phase 1, Early Phase 1 15663-27-1 2767 441203 84093
32
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
33
Epirubicin Approved Phase 2, Phase 3,Phase 1 56420-45-2 41867
34
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
35
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
36
Dalteparin Approved Phase 3,Phase 2 9005-49-6
37
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 46507594 772
38
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
39
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
40
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
41
Ticlopidine Approved Phase 3 55142-85-3 5472
42
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
43
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
45 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
46
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124 9877265
47
Camptothecin Experimental Phase 3,Phase 2,Phase 1,Early Phase 1 7689-03-4
48
Irofulven Investigational Phase 3,Phase 2 158440-71-2
49
tipifarnib Investigational Phase 3,Phase 2 192185-72-1 159324
50 BB 1101 Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 681)

# Name Status NCT ID Phase Drugs
1 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
2 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
3 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
5 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
6 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
7 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
8 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
9 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
12 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
13 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
14 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
15 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
16 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
17 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
18 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
19 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
20 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
21 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
22 Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
23 Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer Completed NCT00033735 Phase 3 fluorouracil;Irofulven
24 Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
25 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer Completed NCT00099294 Phase 3 Glufosfamide
26 Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
27 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
28 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
29 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
30 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
31 Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
32 Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
33 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
34 Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas Completed NCT00003029 Phase 3 cisplatin;fluorouracil
35 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
36 Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
37 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
38 Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
39 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
40 Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
41 Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
42 Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
43 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
44 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
45 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Recruiting NCT02072616 Phase 3
46 EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study) Recruiting NCT02336672 Phase 2, Phase 3
47 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
48 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
49 Neoadjuvant Treatment in Resectable Pancreatic Cancer Recruiting NCT01900327 Phase 3 Gemcitabine neoadjuvant;Gemcitabine adjuvant
50 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Recruiting NCT02184195 Phase 3 Olaparib;Olaparib;Placebo;Placebo

Search NIH Clinical Center for Pancreas Adenocarcinoma

Genetic Tests for Pancreas Adenocarcinoma

Genetic tests related to Pancreas Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 28

Anatomical Context for Pancreas Adenocarcinoma

MalaCards organs/tissues related to Pancreas Adenocarcinoma:

38
Pancreas, Lung, Liver, Breast, Endothelial, Lymph Node, Colon

Publications for Pancreas Adenocarcinoma

Articles related to Pancreas Adenocarcinoma:

(show top 50) (show all 653)
# Title Authors Year
1
Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. ( 29452076 )
2018
2
Paraneoplastic Stiff Person Syndrome Secondary to Pancreatic Adenocarcinoma. ( 29110193 )
2018
3
Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. ( 29448308 )
2018
4
The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. ( 29033025 )
2018
5
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. ( 28087305 )
2017
6
Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. ( 28081546 )
2017
7
Strategies to improve local control of resected pancreas adenocarcinoma. ( 28317586 )
2017
8
Pancreas adenocarcinoma: novel therapeutics. ( 28705007 )
2017
9
Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis. ( 28815403 )
2017
10
Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. ( 28677209 )
2017
11
Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. ( 29306522 )
2017
12
Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas. ( 28742845 )
2017
13
Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic adenocarcinoma. ( 28260012 )
2017
14
Discrimination of CD44 and Oct3/4 Expression in Pancreatic Adenocarcinoma from Benign Pancreatic Ducts in Small Biopsy Specimens. ( 28464601 )
2017
15
Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma. ( 28054562 )
2017
16
Differentially regulated ADAMTS1, 8, 9, and 18 in pancreas adenocarcinoma. ( 29358995 )
2017
17
PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. ( 28656348 )
2017
18
Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. ( 28078482 )
2017
19
Pancreatic adenocarcinoma up-regulated factor has oncogenic functions in oral squamous cell carcinoma. ( 27706833 )
2017
20
Preface: pancreas adenocarcinoma. ( 28705000 )
2017
21
Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. ( 28092668 )
2017
22
Progesterone inhibits proliferation and modulates expression of proliferation-Related genes in classical progesterone receptor-negative human BxPC3 pancreatic adenocarcinoma cells. ( 27449817 )
2017
23
Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. ( 29156888 )
2017
24
The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. ( 28000627 )
2016
25
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma. ( 26754455 )
2016
26
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. ( 27891190 )
2016
27
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. ( 27896469 )
2016
28
Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma. ( 25924930 )
2016
29
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. ( 28028360 )
2016
30
Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. ( 27281208 )
2016
31
Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. ( 27183137 )
2016
32
Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. ( 27203738 )
2016
33
Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma. ( 27368013 )
2016
34
A classical case of non-bacterial thrombotic endocarditis from pancreatic adenocarcinoma presenting as multiple strokes, myocardial infarction and acute limb ischaemia. ( 28031849 )
2016
35
The role of S100P and IMP3 in the cytologic diagnosis of pancreatic adenocarcinoma. ( 27839709 )
2016
36
Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. ( 27497971 )
2016
37
A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort. ( 26646278 )
2016
38
Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. ( 27358244 )
2016
39
Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. ( 27993507 )
2016
40
IntegrinI^1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. ( 27289231 )
2016
41
Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. ( 28017812 )
2016
42
Biomarkers in pancreatic adenocarcinoma: current perspectives. ( 28003762 )
2016
43
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. ( 27532020 )
2016
44
Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma. ( 27999192 )
2016
45
Multidetector computer tomography in the pancreatic adenocarcinoma assessment: an update. ( 27891175 )
2016
46
Radical resection of T1 pancreatic adenocarcinoma with a pseudocyst of the tail due to acute obstructive pancreatitis: report of a case. ( 27900729 )
2016
47
T-cell programming in pancreatic adenocarcinoma: a review. ( 27910859 )
2016
48
Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma. ( 27939096 )
2016
49
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. ( 27015568 )
2016
50
Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma. ( 26692443 )
2016

Variations for Pancreas Adenocarcinoma

ClinVar genetic disease variations for Pancreas Adenocarcinoma:

6 (show top 50) (show all 62)
# Gene Variation Type Significance SNP ID Assembly Location
1 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
2 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
9 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
10 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
21 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
24 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
25 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
28 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
29 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
30 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
31 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
32 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
33 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
34 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
35 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
36 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
37 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
38 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
39 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
40 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
41 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
42 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
43 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
44 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
45 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
46 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
47 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
48 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
49 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
50 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796

Cosmic variations for Pancreas Adenocarcinoma:

9 (show top 50) (show all 1580)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5575704 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 8
2 COSM5575790 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 8
3 COSM5576102 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 8
4 COSM5576231 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 8
5 COSM5576098 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 8
6 COSM3732832 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 8
7 COSM5576197 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 8
8 COSM926359 WT1 stomach,NS,carcinoma,adenocarcinoma c.1298G>A p.R433H 8
9 COSM20570 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 8
10 COSM3732855 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 8
11 COSM3732971 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 8
12 COSM3732707 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 8
13 COSM3732771 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 8
14 COSM3732767 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 8
15 COSM5575712 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8
16 COSM1094394 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8
17 COSM5576247 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2803G>T p.A935S 8
18 COSM5575753 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2357G>A p.R786H 8
19 COSM5576069 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2143C>T p.R715W 8
20 COSM5576203 TRRAP stomach,NS,carcinoma,adenocarcinoma c.8165C>T p.P2722L 8
21 COSM5575742 TRRAP stomach,NS,carcinoma,adenocarcinoma c.622G>A p.E208K 8
22 COSM20551 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5117G>A p.R1706H 8
23 COSM2866680 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5956C>T p.R1986W 8
24 COSM5575878 TRRAP stomach,NS,carcinoma,adenocarcinoma c.10447G>A p.A3483T 8
25 COSM20550 TRRAP stomach,NS,carcinoma,adenocarcinoma c.477A>G p.K159K 8
26 COSM5576201 TRRAP stomach,NS,carcinoma,adenocarcinoma c.2075A>G p.Y692C 8
27 COSM20561 TRPM7 stomach,NS,carcinoma,adenocarcinoma c.2488A>G p.M830V 8
28 COSM1542406 TRIO stomach,NS,carcinoma,adenocarcinoma c.6611A>G p.K2204R 8
29 COSM5575966 TRIM33 stomach,NS,carcinoma,adenocarcinoma c.817C>A p.P273T 8
30 COSM5575609 TRIM33 stomach,NS,carcinoma,adenocarcinoma c.1231C>T p.H411Y 8
31 COSM5576260 TRIM24 stomach,NS,carcinoma,adenocarcinoma c.3115C>T p.R1039C 8
32 COSM5576172 TRIM24 stomach,NS,carcinoma,adenocarcinoma c.706G>C p.E236Q 8
33 COSM5576261 TRIM24 stomach,NS,carcinoma,adenocarcinoma c.3013C>T p.R1005C 8
34 COSM5576173 TRIM24 stomach,NS,carcinoma,adenocarcinoma c.706G>C p.E236Q 8
35 COSM5575610 TPR stomach,NS,carcinoma,adenocarcinoma c.3721A>G p.S1241G 8
36 COSM10654 TP53 stomach,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 8
37 COSM10663 TP53 stomach,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 8
38 COSM10905 TP53 stomach,NS,carcinoma,adenocarcinoma c.451C>T p.P151S 8
39 COSM43606 TP53 stomach,NS,carcinoma,adenocarcinoma c.734G>A p.G245D 8
40 COSM10656 TP53 stomach,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 8
41 COSM10648 TP53 stomach,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 8
42 COSM10704 TP53 stomach,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 8
43 COSM11148 TP53 stomach,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 8
44 COSM11073 TP53 stomach,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 8
45 COSM10709 TP53 stomach,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 8
46 COSM45620 TP53 stomach,NS,carcinoma,adenocarcinoma c.704A>C p.N235T 8
47 COSM11501 TP53 stomach,NS,carcinoma,adenocarcinoma c.823T>G p.C275G 8
48 COSM43844 TP53 stomach,NS,carcinoma,adenocarcinoma c.613T>G p.Y205D 8
49 COSM10808 TP53 stomach,NS,carcinoma,adenocarcinoma c.488A>G p.Y163C 8
50 COSM10651 TP53 stomach,NS,carcinoma,adenocarcinoma c.530C>G p.P177R 8

Expression for Pancreas Adenocarcinoma

Search GEO for disease gene expression data for Pancreas Adenocarcinoma.

Pathways for Pancreas Adenocarcinoma

Pathways related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 AKT1 CDH1 CDKN2A HRAS IL7 KRAS
2
Show member pathways
13.62 AKT1 CDH1 HRAS IFNG IL7 KRAS
3
Show member pathways
13.44 AKT1 HRAS IFNG IL7 KRAS MAP2K2
4
Show member pathways
13.07 AKT1 CDH1 HRAS KRAS MAP2K2 TP53
5
Show member pathways
13.06 AKT1 BRCA2 CDH1 CDKN2A HRAS KRAS
6
Show member pathways
13.05 AKT1 HRAS IL7 KRAS MAP2K2 TP53
7
Show member pathways
13 AKT1 BRCA2 HRAS KRAS MAP2K2 TP53
8
Show member pathways
12.88 AKT1 CDKN2A HRAS KRAS MAP2K2 TP53
9
Show member pathways
12.84 AKT1 HRAS IL7 KRAS MAP2K2
10 12.83 AKT1 HRAS KRAS MAP2K2 TP53
11
Show member pathways
12.8 AKT1 CDH1 HRAS KRAS MAP2K2
12
Show member pathways
12.78 AKT1 CDH1 HRAS KRAS MAP2K2 TP53
13
Show member pathways
12.73 AKT1 HRAS IFNG KRAS MAP2K2 TP53
14
Show member pathways
12.67 AKT1 HRAS IFNG KRAS TP53
15
Show member pathways
12.64 AKT1 CDKN2A HRAS KRAS MAP2K2 TP53
16
Show member pathways
12.64 AKT1 BRCA2 CDH1 CDKN2A HRAS KRAS
17
Show member pathways
12.63 AKT1 HRAS KRAS MAP2K2 SMAD4 TP53
18 12.59 CDKN2A HRAS KRAS MAP2K2 TP53
19
Show member pathways
12.57 AKT1 HRAS KRAS MAP2K2 TP53
20
Show member pathways
12.55 AKT1 HRAS KRAS MAP2K2 TP53
21
Show member pathways
12.51 AKT1 HRAS KRAS MAP2K2 TP53
22
Show member pathways
12.5 AKT1 HRAS IFNG KRAS MAP2K2
23
Show member pathways
12.47 AKT1 HRAS KRAS MAP2K2
24
Show member pathways
12.46 AKT1 HRAS KRAS MAP2K2
25
Show member pathways
12.46 AKT1 HRAS MAP2K2 TP53
26 12.46 AKT1 CDKN2A HRAS KRAS SMAD4 TP53
27
Show member pathways
12.46 AKT1 CDH1 HRAS KRAS MAP2K2 MUC1
28
Show member pathways
12.45 AKT1 HRAS KRAS MAP2K2
29
Show member pathways
12.43 HRAS KRAS MAP2K2 TP53
30 12.43 CDH1 CDKN2A SMAD4 TP53
31
Show member pathways
12.43 AKT1 HRAS KRAS MAP2K2
32
Show member pathways
12.43 AKT1 HRAS IFNG IL7
33
Show member pathways
12.4 AKT1 HRAS KRAS MAP2K2
34
Show member pathways
12.39 AKT1 HRAS KRAS MAP2K2
35 12.37 AKT1 HRAS KRAS MAP2K2 TP53
36 12.36 CDKN2A HRAS KRAS TP53
37
Show member pathways
12.34 AKT1 HRAS KRAS MAP2K2 TP53
38
Show member pathways
12.3 AKT1 HRAS KRAS MAP2K2
39
Show member pathways
12.3 AKT1 HRAS KRAS MAP2K2 TP53
40
Show member pathways
12.27 AKT1 HRAS KRAS MAP2K2
41 12.26 AKT1 HRAS KRAS MAP2K2
42
Show member pathways
12.24 AKT1 HRAS KRAS MAP2K2 TP53
43
Show member pathways
12.22 AKT1 HRAS KRAS MAP2K2
44
Show member pathways
12.22 AKT1 HRAS KRAS TP53
45
Show member pathways
12.21 AKT1 HRAS KRAS MAP2K2 TP53
46 12.19 AKT1 CDKN2A HRAS KRAS MAP2K2 TP53
47 12.16 AKT1 BRCA2 CDH1 KRAS SMAD4 TP53
48 12.15 AKT1 HRAS KRAS MAP2K2 SMAD4
49 12.14 AKT1 CDKN2A KRAS TP53
50 12.14 AKT1 HRAS KRAS TP53

GO Terms for Pancreas Adenocarcinoma

Cellular components related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 AKR7A3 AKT1 BRCA2 CDH1 CDKN2A ERCC1

Biological processes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 CDKN2A FOXP3 HRAS SMAD4 TP53
2 positive regulation of protein phosphorylation GO:0001934 9.81 AKT1 HRAS IFNG KRAS
3 positive regulation of gene expression GO:0010628 9.8 CDKN2A FOXP3 HRAS IFNG KRAS TP53
4 cell cycle arrest GO:0007050 9.78 CDKN2A HRAS IFNG TP53
5 negative regulation of gene expression GO:0010629 9.77 AKT1 FOXP3 HRAS IFNG MAP2K2
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.76 HRAS KRAS MUC1 MUC4
7 cell proliferation GO:0008283 9.73 AKT1 BRCA2 ERCC1 HRAS SMAD4 TP53
8 epidermal growth factor receptor signaling pathway GO:0007173 9.7 AKT1 HRAS KRAS
9 nucleotide-excision repair GO:0006289 9.67 BRCA2 ERCC1 TP53
10 cell aging GO:0007569 9.61 BRCA2 HRAS TP53
11 positive regulation of organ growth GO:0046622 9.58 AKT1 IL7
12 negative regulation of interleukin-17 production GO:0032700 9.58 FOXP3 IFNG
13 response to X-ray GO:0010165 9.58 BRCA2 ERCC1 TP53
14 response to isolation stress GO:0035900 9.57 HRAS KRAS
15 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.56 CDKN2A IFNG
16 Ras protein signal transduction GO:0007265 9.46 CDKN2A HRAS KRAS TP53
17 positive regulation of transcription, DNA-templated GO:0045893 9.28 AKT1 BRCA2 CDH1 CDKN2A FOXP3 MAP2K2
18 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 BRCA2 MUC1 TP53
19 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 AKT1 CDKN2A FOXP3 HRAS PTF1A SMAD4

Molecular functions related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 AKR7A3 AKT1 BRCA2 CDH1 CDKN2A ERCC1
2 protein C-terminus binding GO:0008022 8.92 BRCA2 ERCC1 HRAS TP53

Sources for Pancreas Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....